Meda passes Xerese and Elidel on to Valeant in NAFTA for $76 million plus royalties
This article was originally published in Scrip
Executive Summary
Following yesterday's news that Medivir is selling rights to the cold sore treatment Xerese in the US, Canada and Mexico to Meda for $45 million, Meda has confirmed it is in turn selling the Xerese rights, along with North American rights to the atopic dermatitis treatment Elidel, to Valeant Pharmaceuticals.